PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma

• Main Authors: Min Luo (Author), Yuhui Xia (Author), Fang Wang (Author), Hong Zhang (Author), Danting Su (Author), Chaoyue Su (Author), Chuan Yang (Author), Shaocong Wu (Author), Sainan An (Author), Suxia Lin (Author), Liwu Fu (Author)
• Format: Book
• Published: Elsevier, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ERK pathway regulated the programmed death ligand-1 (PD-L1) expression which was linked to the response of programmed death-1 (PD-1)/PD-L1 blockade therapy. So it is deducible that ERK inhibitor could enhance the efficacy of PD-1 inhibitor in cancer immunotherapy. In this study, PD0325901, an oral p...